Cytochrome P450 Enzyme Inhibitors
Inhibition of hepatic cytochrome P450 isoenzymes (CYP3A4, CYP2D6, CYP2C9) decreases clearance of co-administered drugs, sharply increasing their plasma concentrations and risk of adverse events.
Inhibition of hepatic cytochrome P450 isoenzymes (CYP3A4, CYP2D6, CYP2C9) decreases clearance of co-administered drugs, sharply increasing their plasma concentrations and risk of adverse events.
Inhibits CYP2C9 and epoxide hydrolase, elevating lamotrigine and carbamazepine levels.
Inhibits CYP2E1 and CYP2C19, interacting significantly with phenytoin and carbamazepine.
Potent non-specific inhibitor of multiple CYP isoforms (CYP1A2, 2C9, 2D6, 3A4); antiandrogenic side effects.
Fluconazole, Itraconazole, Voriconazole are potent inhibitors of CYP3A4 and CYP2C9.
Potent CYP2D6 inhibitor, blocking metabolism of codeine, tamoxifen, and beta-blockers.
Acute heavy binge drinking saturates and competitively inhibits CYP2E1.
Inhibits hepatic microsomes; historically linked to gray baby syndrome.
Macrolides (excluding azithromycin) strongly inhibit CYP3A4, dangerously elevating statin and theophylline levels.
Inhibits CYP2C9, causing dangerous rises in Warfarin INR and sulfonylurea hypoglycemia.
Inhibits CYP1A2, leading to theophylline toxicity.
Inhibits CYP2C19, reducing activation of the clopidogrel prodrug.
Inhibits CYP2C9 (disulfiram-like reaction with ethanol, increases warfarin effect).